STAY UP-TO-DATE

By signing up and joining our community of healthcare providers, you’ll receive relevant updates to keep you informed

From the latest research to patient resources, we’re here to provide you with the tools you need to help treat the inflammatory lesions of rosacea

DOWNLOAD HERE!

There is one final step before you can gain access to this resource

By providing us with your details, we will let you know when relevant information on your chosen interests becomes available

THANK YOU FOR SUBSCRIBING!

We’ll be back in touch with more information to ensure you stay up-to-date and connected to the latest rosacea insights

THANK YOU FOR DOWNLOADING OUR RESOURCES!

For more information on how ORACEA Capsules can safely and
effectively treat your rosacea patients, return to our website1–3

IMPORTANT SAFETY INFORMATION

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established

You are encouraged to report negative side effects of prescription drugs to the FDA
Visit www.fda.gov/medwatch or call 1-800-FDA-1088

*30 mg immediate release and 10 mg delayed release beads

  1. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2014
  2. Del Rosso JQ, Oet al. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008;7(8):573–576
  3. Bhatia N. ORACEA 40 mg capsules for papulopustular rosacea. The Dermatologist. 2013;6(21s):1–4. Available at: https://www.hmpgloballearningnetwork.com/site/thederm/site/cathlab/event/oracea-40-mg-capsules-papulopustular-rosacea-1. Last accessed: September 2021
  4. Theobald K, et al. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6(5):221–226
  5. Wise RD. Sub microbial doxycycline and rosacea. Compr Ther. 2007;33(2):78–81

US-ORC-2100045